PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice
Germline BRCA1/2 mutations account for about 10% of all breast cancer. BRCA1/2 proteins are involved in homologous recombination - DNA double-strand break repair mechanism. Poly-(ADP ribose) polymerases (PARP) are required to repair DNA single-strand breaks through base excision repair. PARP inhibit...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Russo |
| Udgivet: |
Remedium Group LLC
2020-07-01
|
| Serier: | Медицинский совет |
| Fag: | |
| Online adgang: | https://www.med-sovet.pro/jour/article/view/5701 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|